Prexige: new coxib for OA, dysmenorrhoea and acute pain
Authors
Abstract
Lumiracoxib (Prexige) is a new COX‐2 inhibitor that is currently licensed for use in osteoarthritis (OA), primary dysmenorrhoea and acute pain. Here, Professor Scott focusses on its safety and efficacy and discusses its role in managing pain in OA patients. Copyright © 2006 Wiley Interface Ltd
Digital Object Identifier (DOI)
10.1002/psb.422 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
